Carlos D Nuñez-Amaro, Aura Ileana Moreno-Vega, Elva Adan-Castro, Magdalena Zamora, Renata Garcia-Franco, Paulina Ramirez-Neria, Marlon Garcia-Roa, Yolanda Villalpando, Juan Pablo Robles, Gabriela Ramirez-Hernandez, Mariana Lopez, Jorge Sanchez, Ellery Lopez-Star, Thomas Bertsch, Gonzalo Martinez de la Escalera, Ma Ludivina Robles-Osorio, Jakob Triebel, Carmen Clapp
Purpose: High circulating levels of the hormone prolactin (PRL) protect against experimental diabetic retinopathy (DR) due to the retinal accumulation of vasoinhibin, a PRL fragment that inhibits blood vessel permeability and growth. A phase 2 clinical trial is investigating a new therapy for DR based on elevating serum PRL levels with levosulpiride, a prokinetic dopamine D2 receptor blocker. Here, we tested whether levosulpiride-induced hyperprolactinemia elevates PRL and vasoinhibin in the vitreous of volunteer patients with proliferative DR (PDR) undergoing elective pars plana vitrectomy...
August 2020: Translational Vision Science & Technology